Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial diseas...
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 204
- Registration Number
- NCT05166538
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Effects of Edoxaban on Platelet Aggregation
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 70
- Registration Number
- NCT05122455
- Locations
- 🇧🇷
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 2334
- Registration Number
- NCT04981041
- Locations
- 🇩🇪
Deutsches Herzzentrum München, Munich, Bayern, Germany
🇩🇪Kerckhoff-Klinik GmbH, Herzzentrum, Bad Nauheim, Germany
🇩🇪Universitätsklinikum Freiburg, Universitäts-Herzzentrum Klinik für Kardiologie & Angiologie, Campus Bad Krozingen, Bad Krozingen, Germany
Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
- Conditions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT04847752
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 424
- Registration Number
- NCT04824911
- Locations
- 🇨🇳
Yenchu Huang, Chiayi City, Taiwan
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry
- Conditions
- Interventions
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 125
- Registration Number
- NCT04822363
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04809818
- Locations
- 🇺🇸
Lumosa Phase 1 Unit, Cypress, California, United States
AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 135
- Registration Number
- NCT04770012
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
🇨🇦Toronto General Hospital UHN, Toronto, Ontario, Canada
🇨🇦St.Pauls Hospital, Vancouver, British Columbia, Canada
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 2230
- Registration Number
- NCT04695106
- Locations
- 🇵🇱
Cardiac lntensive Care Unit, First Department of Cardiology, University Clinical Centre in Gdańsk, Gdańsk, Pomorskie, Poland
Drug Interaction Study of MGL-3196 With Clopidogrel
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- Madrigal Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04671069
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.